Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke

CNS Drug Reviews

Volumn 9, Issue 3, 2003, Pages 253-262

  Lapchak, Paul A ^a,b,c   Araujo, Dalia M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Free radicals; Hemorrhage; Neuroprotection; Nitrone; Oxidative stress; Spin trap

Indexed keywords

DISUFENTON SODIUM; NITRONE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW;

EID: 0141954290     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00252.x     Document Type: Review

References (59)

1. Alberts MJ. Diagnosis and treatment of ischemic stroke. Am J Med 1999;106:211-221.
2. Anderson DE, Yuan XJ, Tseng CM, Rubin LJ, Rosen GM, Tod ML. Nitrone spin-traps block calcium channels and induce pulmonary artery relaxation independent of free radicals. Biochem Biophys Res Commun 1993;193:878-885.
3. Anderson KM, Ells G, Bonomi P, Harris JE. Free radical spin traps as adjuncts for the prevention and treatment of disease. Med Hypotheses 1999;52:53-57.
4. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:452-457.
5. Becker DA. Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol Life Sci 1999;56:626-633.
6. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-3040.
7. Chamulitrat W, Jordan SJ, Mason RP, Saito K, Cutler RG. Nitric oxide formation during light-induced decomposition of phenyl N- tert-butylnitrone. J Biol Chem 1993;268:11520-11527.
8. Chen GM, Bray TM, Janzen EG, McCay PB. Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats. Free Radic Res Commun 1990;9:317-323.
9. Dehouck MP, Cecchelli R, Richard Green A, Renftel M, Lundquist S. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res 2002;955:229-235.
10. Dimagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391-397.
11. Edenius C, Strid S, Breitholtz-Emanuelsson A, Dalin L, Jerling M, Fransson B. NXY-059, the first nitrone being developed for stroke, is safe and well tolerated in young and elderly healthy volunteers. Cerebrovasc Dis 1999;9:Abs 102.
12. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998;18:667-682.
13. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236-245.
14. Floyd RA, Hensley K, Jaffery F, et al. Increased oxidative stress brought on by pro-inflammatory cytokines in neurodegenerative processes and the protective role of nitrone-based free radical traps. Life Sci 1999;65: 1893-1899.
15. Folbergrova J, Zhao Q, Katsura K, Siesjo BK. N-tert-butyl-alpha-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 1995;92:5057-5061.
16. Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol 2002;29:1030-1034.
17. Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998;29:429-432.
18. Hahn SM, Lepinski DL, DeLuca AM, Mitchell JB, Pellmar TC. Neurophysiological consequences of nitroxide antioxidants. Can J Physiol Pharmacol 1995;73:399-403.
19. Hassan WN, Cantuti-Castelevetri I, Denisova NA, Yee AS, Joseph JA, Paulson KE. The nitrone spin trap PBN alters the cellular response to H(2)O(2): Activation of the EGF receptor/ERK pathway. Free Radic Biol Med 2002;32:551-561.
20. Hensley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev Neurobiol 1997;40:299-317.
21. Hensley K, Pye QN, Maidt ML, et al. Interaction of alpha- phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 1998;71:2549-2557.
22. Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 1999;30:1326-1332.
23. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon. Neurosurgery 1998;43:1382-1396; discussion 1396-1397.
24. Kotake Y. Pharmacologic properties of phenyl N-tert-butylnitrone. Antioxid Redox Signal 1999;1:481-499.
25. Kuroda S, Katsura K, Hillered L, Bates TE, Siesjo BK. Delayed treatment with alpha-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol Dis 1996;3:149-157.
26. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-787.
27. Lapchak PA. Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep 2002;2:38-43.
28. Lapchak PA. Development of thrombolytic therapy for stroke: A perspective. Exp Opin Invest Drugs 2002; 11:1623-1632.
29. Lapchak PA, Araujo DM. Reducing bleeding complications after thrombolytic therapy for stroke: Clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 2001;15:819-829.
30. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1, 3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33: 1411-1415.
31. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: Combination studies with tissue plasminogen activator. Stroke 2002; 33:1665-1670.
32. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279-2284.
33. Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32:675-680.
34. Lees KR, Barer D, Ford GA, et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003; 34:482-487.
35. Lewen A, Skoglosa Y, Clausen F, et al. Paradoxical increase in neuronal DNA fragmentation after neuroprotective free radical scavenger treatment in experimental traumatic brain injury. J Cereb Blood Flow Metab 2001;21:344-350.
36. Li PA, He QP, Nakamura L, Csiszar K. Free radical spin trap alpha-phenyl-N-tert-butyl-nitron inhibits caspase-3 activation and reduces brain damage following a severe forebrain ischemic injury. Free Radic Biol Med 2001;31:1191-1197.
37. Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic Res 2001;34:417-426.
38. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32: 190-198.
39. Milatovic D, Radic Z, Zivin M, Dettbarn WD. Atypical effect of some spin trapping agents: Reversible inhibition of acetylcholinesterase. Free Radic Biol Med 2000;28:597-603.
40. Mori H, Arai T, Ishii H, et al. Neuroprotective effects of pterin-6-aldehyde in gerbil global brain ischemia: Comparison with those of alpha-phenyl-N-tert-butyl nitrone. Neurosci Lett 1998;241:99-102.
41. Nakashima M, Niwa M, Iwai T, Uematsu T. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med 1999;26:722-729.
42. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 2001:40:433-439.
43. Sang H, Wallis GL, Stewart CA, Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharide-administered rats and their inhibition by phenyl-N-tert-butylnitrone (PBN). Arch Biochem Biophys 1999;363:341-348.
44. Schulz JB, Matthews RT, Jenkins BG, Brar P, Beal MF. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J Cereb Blood Flow Metab 1995;15:948-952.
45. Siesjö BK, Siesjö P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996;13:247-268.
46. Siesjö BK, Katsura K, Zhao Q, et al. Mechanisms of secondary brain damage in global and focal ischemia: A speculative synthesis. J Neurotrauma 1995;12:943-956.
47. Simoons ML. Risk-benefit of thrombolysis. Cardiol Clin 1995;13:339-345.
48. Stewart CA, Hyam K, Wallis G, et al. Phenyl-N-tert-butylnitrone demonstrates broad-spectrum inhibition of apoptosis-associated gene expression in endotoxin-treated rats. Arch Biochem Biophys 1999;365:71-74.
49. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002;58:409-415.
50. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103-112.
51. Thomas CE, Ku G, Kalyanaraman B. Nitrone spin trap lipophilicity as a determinant for inhibition of low density lipoprotein oxidation and activation of interleukin-1 beta release from human monocytes. J Lipid Res 1994;35:610-619.
52. Thomas CE, Ohlweiler DF, Carr AA, et al. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem 1996;271:3097-3104.
53. Tsuji M, Inanami O, Kuwabara M. Neuroprotective effect of alpha-phenyl-N-tert-butylnitrone in gerbil hippocampus is mediated by the mitogen-activated protein kinase pathway and heat shock proteins. Neurosci Lett 2000;282:41-44.
54. Vrbjar N, Zollner S, Haseloff RF, Pissarek M, Blasig IE. PBN spin trapping of free radicals in the reperfusion-injured heart. Limitations for pharmacological investigations. Mol Cell Biochem 1998;186:107-115.
55. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350:607-614.
56. Yang Y, Li Q, Shuaib A. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2- sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia. Exp Neurol 2000;163:39-45.
57. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjö BK. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 2002;932:99-109.
58. Yue TL, Gu JL, Lysko PG, Cheng HY, Barone FC, Feuerstein G. Neuroprotective effects of phenyl-t-butyl-nitrone in gerbil global brain ischemia and in cultured rat cerebellar neurons. Brain Res 1992;574:193-197.
59. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46-50.